In this study 302 samples from 273 patients with metastatic colorectal cancer were tested for 7 most common mutations on codon 12 and 13 of the KRAS gene. Among the tested patients 54.5% had a wt-KRAS genotype and 45.5% had a mutated KRAS genotype. Among the cetuximab therapy responders, 85.7% had a wt-KRAS genotype. We have shown that the RT-PCR method introduced to discriminate between anti-EGFR therapy responders and non-responders is efficient, reliable and quickly applicable.
The BRCA1 and BRCA2 mutation spectrum and mutation detection rates were investigated in 521 subjects from 322 unrelated Slovenian cancer families with breast and/or ovarian cancer. 18 different mutations were found in BRCA1 and 13 in BRCA2 gene in 96 unrelated families. Among the mutations detected, 5 mutations in BRCA1 and 4 mutations in BRCA2 have not been described in other populations until now. The most frequent mutations in our population were c.181T ) G, c.1687C ) T, c.5266dupC and c.844_850dupTCATTAC in BRCA1 gene and c.7806-2A ) G, c.5291C ) G and c.3978insTGCT in BRCA2 gene.
Authors report results of a online survey available in 10 different languages in 8,178 individuals from Europe (73%), Australia (12%), United States (7%) and Israel (2%) about predictors of sun protection behaviors. Results showed that a substantial proportion reported inadequate sun protection behaviors including respondents with a previous melanoma
Authors developed nomograms predicting probability of non-sentinel node metastases in breast cancer patients with a positive sentinel lymph node. The nomograms include data of the preoperative ultrasound examination of the axillary lymh nodes and therefore more accurately predict the non sentinel node status in comparison to other already developed nomograms elsewhere.
Survival in breast cancer patients by age group was estimated, focussing on those covered by screening programmes, using data from 12 European population-based cancer registries. Some of the geographical differences in overall survival are even larger when considering age groups, in particular between Western and Eastern European countries. Furthermore, some of the differences in survival within the Northern and Western European areas could be due to variations in the implementation of screening programmes rather than economic inequalities.